Previous studies have demonstrated that the Onco-P20 conjugate interacts with CD44, enters cells through a receptor-mediated mechanism, and exerts a concentration-dependent inhibitory effect on tumor cells [42,67,68]. This evidence concerns the gene CD44 and neoplasm.